FMP
AMEX
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
0.35 USD
-0.0006 (-0.171%)
Valuation Date:
May 1, 2024 4:00 PM
Share Price on Valuation Date
$0.35
Stock Beta
0.959
Shares Outstanding
759692000